Search CBIO
CRESCENT BIOPHARMA, INC.
Nasdaq · CIK 1253689
Last close14.32
Daily change+0.06 (0.42%)
10 Years gain+2361.61%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CBIO · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
30.2Momentum
n/aAcceleration
n/aConfidence
77.0Annual Revenue6
Quarterly Revenue22
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.7 / 25
Quality6.8 / 25
Capital Efficiency0.0 / 20
Balance Sheet9.2 / 15
Shareholder Economics5.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Negative FCF · HIGHLatest free cash flow is negative.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM1,828.54%OK
Revenue CAGR 3Y-10.3%OK
Gross Margin270.36%OK
Operating Margin-8,310.59%OK
FCF Margin-5,385.27%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO3.08xOK
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenue1,409.72%OK
SBC / FCF-26.18%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $10.84M | $10.84M | -$152.63M | -$71.53M | -$72.45M | 100% | -1,407.52% | -668.12% | n/a | n/a |
| 2024 FY Dec 31, 2024 | n/a | $0.00 | -$40.04M | n/a | n/a | n/a | n/a | n/a | n/a | 64.48M |
| 2024 FY Dec 31, 2023 | n/a | $10,000.00 | -$39.28M | -$34.88M | -$34.90M | n/a | n/a | n/a | n/a | 63.34M |
| 2023 FY Dec 31, 2022 | n/a | $75,000.00 | -$47.40M | -$46.46M | -$46.54M | n/a | n/a | n/a | n/a | 52.53M |
| 2023 FY Dec 31, 2021 | n/a | $1.16M | -$63.45M | -$57.49M | -$57.50M | n/a | n/a | n/a | n/a | 51.45M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.04M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-028362, 0001628280-26-050869 |
| Revenue Growth TTM | 1,828.54% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-028362, 0001628280-26-050869 |
| Revenue CAGR 3Y | -10.3% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011983 |
| Revenue CAGR 5Y | -6.6% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-011983 |
| Gross Profit CAGR 3Y | -10.3% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011983 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-028362, 0001628280-26-050869 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-028362, 0001628280-26-050869 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 270.36% | Gross Profit / Revenue | OK | 0001628280-26-028362, 0001628280-26-050869 |
| Operating Margin | -8,310.59% | Operating Income / Revenue | OK | 0001628280-26-028362, 0001628280-26-050869 |
| FCF Margin | -5,385.27% | (CFO - CapEx) / Revenue | OK | 0001628280-26-028362, 0001628280-26-050869 |
| Net Debt / CFO | 3.08x | Net Debt / CFO | OK | 0001628280-26-050869, 0001628280-26-028362 |
| Current Ratio | 9.66x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 1,409.72% | SBC / Revenue | OK | 0001628280-26-028362, 0001628280-26-050869 |
| SBC / FCF | -26.18% | SBC / FCF | OK | 0001628280-26-028362, 0001628280-26-050869 |